In addition, breast cancer cells that overexpress the EGF family receptor HER2 exhibit increased metastatic potential compared to mammary counterparts without HER2 overexpression, and this is partially due to the augmented secretion of autocrine TGFβ by such tumor cells, which enhances EMT and their pro-metastatic potential [77]. This evidence concerns the gene ERBB2 and breast cancer.